Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.

Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.

To identify novel agents to treat carbapenem-resistant Acinetobacter baumannii. the Inventors used a nutrient-depleted medium with serum to mimic the in vivo environment. In RPMI with serum, the screen identified rifabutin (RBT) as being 133-fold more potent than rifampin (RIF) against A. baumannii, with MICs of 0.031 μg/ml and 4 μg/ml respectively. No difference in RBT vs. RIF activity was observed when MHII was used as the culture media. RBT possesses markedly superior in efficacy to RIF in murine models of lethal iv and pneumonia models of infection with a hyper-virulent, clinical lung and blood isolate of extreme-drug resistant (XDR) A. baumannii. In both models, RBT significantly improved survival and lowered bacterial burden compared to RIF. RBT is a promising, novel therapeutic option for A. baumannii infections.

To identify novel agents to treat carbapenem-resistant Acinetobacter baumannii. the Inventors used a nutrient-depleted medium with serum to mimic the in vivo environment. In RPMI with serum, the screen identified rifabutin (RBT) as being 133-fold more potent than rifampin (RIF) against A. baumannii, with MICs of 0.031 μg/ml and 4 μg/ml respectively. No difference in RBT vs. RIF activity was observed when MHII was used as the culture media. RBT possesses markedly superior in efficacy to RIF in murine models of lethal iv and pneumonia models of infection with a hyper-virulent, clinical lung and blood isolate of extreme-drug resistant (XDR) A. baumannii. In both models, RBT significantly improved survival and lowered bacterial burden compared to RIF. RBT is a promising, novel therapeutic option for A. baumannii infections.

Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.

Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.

Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.

A composition comprising a cannabinoid and a disruptor compound that removes or substantially removes or reduces the integrity of the outer membrane of a bacterium.

A composition comprising a cannabinoid and a disruptor compound that removes or substantially removes or reduces the integrity of the outer membrane of a bacterium.

Methods for treating, selecting a treatment, and monitoring a treatment for an inflammatory bowel disease in a patient in need are disclosed. Treatments include administering an antifungal compound. The method for selecting and monitoring a treatment includes detecting a biomarker indicative of an amount of the fungus Debaryomyces hansenii within the sample. The treatment is administered if the biomarker is above a threshold level and the biomarker may be monitored before and during treatment. Biomarkers include abundance of fungal DNA in the patient's gut microbiota and anti-fungal antibodies in the blood of the patient.